Evidence-Based Complementary and Alternative Medicine / 2012 / Article / Tab 2

Research Article

Uncaria tomentosa—Adjuvant Treatment for Breast Cancer: Clinical Trial

Table 2

Leukocytes, neutrophils, lymphocytes, and monocytes levels in breast cancer patients before treatment and after 6 cycles of chemotherapy without Uncaria tomentosa supply (Ca group) or receiving 300 mg/day of Uncaria tomentosa (UtCa group).

ParametersCycles
(cells/mm3) 0 1-2 3-4 5-6

Leukocytes
 Control
 UtCa
 Ca
Neutrophils
 Control
 UtCa
 Ca
Lymphocytes
 Control2264 ± 490,6
 UtCa2276 ± 503,32376 ± 708,11627 ± 578,7*1411 ± 596,6*
 Ca2177 ± 453,32284 ± 867,91460 ± 512,5*1208 ± 395,1*
Monocytes
 Control487,6 ± 128,9
 UtCa515,3 ± 169560 ± 322814,9 ± 309#817 ± 444,6
 Ca541,6 ± 161526,6 ± 154654,1 ± 310*#500,9 ± 226*#

Data expressed asmean ± standard deviation.
*Represent difference significant between the Ca and UtCa groups, P <0.05.
#Represent difference significant of the control group, P <0.05 (Student’s t-test).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.